• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Octreotide
    2 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Sandostatin
    Novartis
    RX
    partial basket chart
    Sandostatin

    Antigrowth Hormone. Octreotide 0.05, 0.1, 0.5 mg/ml.
    AMPS (sol. for inject./infus.): 5 x 0.05, 0.1,
    0.5 mg/ml.
    Dosage must be ajust. individ. See lit.
    Prevent. complicats. follow. pancreat.
    surg., symptomat. control and reduct. GH
    and IGF-1 plasma levels in pts. with
    ecromegaly who are inadequate.
    controlled by surg., radiother. or dopamine agonist. Acromegalic unfit or unwilling to undergo surg., or in the interim period until
    radiother. becomes fully affect. Relief of
    sympts. associated with gastroenteropancreat.
    endocrin tumors: carcinoid tumors with features of the carcinoid syndr.; VIPomas; glucagonomas; gastrinomas / Zollinger- Ellison syndr. usually in conjunct. with select
    H2-antagonist ther; insulinomas, for preop.
    control of hypoglycem., for maint. ther.; GRFomas. Not antitumor ther., not
    curative in these pts. Emergency manage.
    Bleed gastro-esoph. varices second. to
    cirrhos. In comb. specific ther. such as
    sclerother.
    C/I: Hypersens.

    Sandostatin LAR
    Novartis
    RX
    partial basket chart
    Sandostatin LAR

    Somatostatin Analog. Octreotide 10, 20, 30 mg.
    VIALS: 1. (2 vehicle amp + 1 inject set).
    By deep intraglut. inject. See lit.
    Acromeg. in pts. adequat. controlled on
    standard dose Sandostatin S.C. in whom
    surg. radiother., or dopamine-agonist tmt.
    inapprop. or ineffect., in latency period bef.
    radiother. becomes fully effect. Endocrine
    gastro-entro-pancreat. (GEP) tumors,
    carcinoid tumors.
    VIALS: 1. (1 prefilled syringe + 2 needles)
    x 20 mg, 30 mg. By deep intraglut.
    inject. See lit.
    Acromeg. in pts. adequat. controlled on
    standard dose Sandostatin S.C. in whom
    surg. radiother. inapprop. or ineffect., in
    latency period bef. radiother. becomes
    fully effect. Endocrine gastro-entropancreat.
    (GEP) tumors, carcinoid
    tumors.

    CLOSE